Description: ArTara Therapeutics, Inc., a clinical-stage company, develops product candidates for patients suffering from rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The company's lead program is TARA-002, a cellular therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. ArTara Therapeutics, Inc. is based in New York, New York.
Home Page: www.protaratx.com
TARA Technical Analysis
345 Park Avenue South
New York,
NY
10010
United States
Phone:
646 844 0337
Officers
| Name | Title |
|---|---|
| Mr. Jesse Shefferman | Co-Founder, Principal Financial Officer, CEO, Pres & Director |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Sr. VP & Chief Scientific Operations Officer |
| Ms. Hannah Fry | Principal Accounting Officer & Controller |
| Ms. Justine O'Malley | Sr. VP of Investor Relations & Corp. Affairs |
| Ms. Mary J. Grendell | Gen. Counsel & Corp. Sec. |
| Ms. Kristine Rosse | Sr. VP & Chief People Officer |
| Dr. Jathin Bandari M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2413 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-10-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |